Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Neoplasms 2Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Breast Neoplasms 1

Interventions

Rituximab 93Cyclophosphamide 72fludarabine phosphate 53Whole-Body Irradiation 43Mycophenolic Acid 40Peripheral Blood Stem Cell Transplantation 39Bortezomib 30Tacrolimus 29Etoposide 29Cyclosporine 28Melphalan 26Filgrastim 26Busulfan 26Methotrexate 24Lenalidomide 23Cytarabine 23ibrutinib 20Vincristine 20Granulocyte Colony-Stimulating Factor 20Antilymphocyte Serum 20Doxorubicin 18Bendamustine Hydrochloride 18Dexamethasone 16Sirolimus 14fludarabine 13Carmustine 13Cord Blood Stem Cell Transplantation 12Calcium Dobesilate 12Radiotherapy 11Prednisone 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Mantle-Cell × cirmtuzumab × Clear all
NCT03088878 2025-02-12

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Oncternal Therapeutics, Inc

Phase 1/2 Completed
95 enrolled 25 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡